The US Food and Drug Administration (FDA) has granted accelerated approval to Ascendis Pharma’s Yuviwel (navepegritide) for ...

Yuviwel, a once-weekly injection, will now compete for market share with BioMarin’s lucrative daily shot Voxzogo.

Ascendis Pharma is spiraling upward by way of its TransCon platform. | Ascendis Pharma is spiraling upward by way of its TransCon platform. For the third time in six years, the Copenhagen-based ...

A Polokwane mother has launched a fund to help children with achondroplasia access a costly treatment unavailable in South Africa.

Navepegritide is indicated for those ages 2 and older with open epiphyses ...

The approval gives Ascendis a window of opportunity to eat into BioMarin's market share, as the latter works on its own ...

The FDA has approved navepegritide (Yuviwel), developed by Ascendis Pharma, for children aged 2 years and older with achondroplasia, the most common form of dwarfism. Navepegritide is a prodrug ...

Achondroplasia, also known as short-limb dwarfism, is associated with neurological symptoms and complications due to ...

GLENS FALLS, N.Y. (NEWS10) – It is Physical Therapy Awareness Month and it’s also Dwarfism Awareness Month and that’s why NEWS10 was at Glens Falls Hospital’s Rehabilitation and Wellness Center.

Sanofi has halted work on a phase 2 candidate for a rare growth disorder as part of a pipeline clear-out that saw the French pharma discontinue two other rare disease assets and one of its mRNA flu ...